Background Prognostic classification approaches are commonly used in clinical practice to predict health outcomes. However, there has been limited focus on use of the general approach for predicting costs. We applied a grouping algorithm designed for large-scale data sets and multiple prognostic factors to investigate whether it improves cost prediction among older Medicare beneficiaries diagnosed with prostate cancer. 
into prognostic groups for predicting survival and guiding treatment receipt. For example, the TNM classification system is a commonly used prognostic tool for defining prognostic groups and classifying primary tumours [2] . The TNM classification system is based on three histological and clinical characteristics of cancer: the tumour extent (T), lymph node involvement (N) and metastasis (M) [2, 3] . It is assumed that patients within a TNM class would share similar characteristics related to disease progression and survival [2] . Therefore, patients within a prognostic group, such as a TNM class, typically receive similar treatment recommendations. It is unknown whether the prognostic system approach can be adapted to predict cost outcomesin particular, when expanded beyond tumour characteristics to include clinical and contextual factors associated with cost accumulation.
In this study, we investigated whether tools for predicting survival can be adapted to investigate cost accumulation over time when applied to the prostate cancer setting. Survival analysis often includes patient demographic and clinical predictors, such as cancer histology, age at diagnosis and comorbid conditions [3] . The results are used to develop survival curves that provide information regarding survival patterns of groups of patients, defined on the basis of either the full sample or stratifying variables. For example, when stratified by defined factors (e.g. cancer stage), each survival curve illustrates the average survival pattern for a group of patients with the same characteristic(s) [i.e. cancer stage]. Since several prognostic factors can be used to predict survival outcomes, a comparison of survival curves across patient groups can be used to identify prognostic factors that are common to the patients represented in each survival curve. When this approach is extended to cost curves and cost accumulation over time, a comparison of cost curves across patient groups should allow us to identify predictors of cost accumulation over time. Accurate cost predictions are necessary for patient care delivery and planning.
Published prognostic systems accomplish the task of identifying groups of patients that are similar on the basis of clinical prognostic factors [1] [2] [3] . The TNM classification scheme is a 'bin model' [2] . TNM prognostic factors are used to create a mutually exclusive and exhaustive partitioning of patients, so that every patient belongs to one bin, and the bins are grouped together into larger bins called 'stages'. The system uses the mean survival of the patients already in the bin to predict what will happen to a new patient placed in that bin. However, the constraint on the number of prognostic factors in the TNM system can affect the quality of the survival prediction. To work around this limitation, new approaches have been introduced to expand the TNM system to accommodate new prognostic factors and increase the accuracy of estimating patient outcomes [3] .
The Ensemble Algorithm for Clustering Cancer Data (EACCD), introduced by Chen et al. [3] , represents an effort to expand the TNM classification. The EACCD admits multiple prognostic factors and increases the outcome prediction accuracy for cancer patients. However, the ensemble clustering method requires a large number of partitioning iterations. Therefore, Qi and Zhou [1] proposed a Grouping Algorithm for Cancer Data (GACD), which uses the weighted clustering method to reduce the computational time and a simulated-annealing Partitioning Around Medoid (PAM) clustering algorithm to increase the clustering accuracy [4] . To the best of our knowledge, these algorithms have not been used to investigate cost accumulation and/or cost prediction in the short term.
Prostate cancer is the most frequently diagnosed noncutaneous cancer and the second leading cause of cancer mortality among men in the USA [5] . The clinical burden of prostate cancer is disproportionately greater among older men; 57 % of those diagnosed with it, and 90 % of those who die from it, are men aged C65 years. The annual cost of treating prostate cancer in the USA amounts to several billion dollars [6] . As the majority of the men diagnosed with prostate cancer are elderly, Medicare bears the greatest economic burden of prostate cancer. Therefore, the objective of this study was to apply a published grouping algorithm [1] in the development of cost curves and investigate their accuracy in predicting cost accumulation over time as a proof of concept among Medicareeligible older men diagnosed with prostate cancer.
Methods
This section describes the GACD [1] and its application to studying survival and cost accumulation, using linked cancer registry and claims data. The analysis involved two main steps: (1) identifying groups of patients based on survival curves using the GACD; and (2) developing cost curves for the groups of patients obtained from the first step.
Data Source
Data for the study were obtained from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database and linked Medicare enrolment and claims files [7] . SEER is a national cancer surveillance network of 18 regional cancer registries, covering approximately 28 % of the US population [7] . The registries record all diagnosed cancers within the region, including detailed information on demographic characteristics, the date of cancer diagnosis, the cancer site, histology and initial treatment [7] . Medicare enrolment and claims files are linked to SEER data at the individual level to record medical service utilization by Medicare beneficiaries before and after their cancer diagnosis. The claims data available for this study included claims from 2000 through 2009 for men diagnosed with prostate cancer between 2000 and 2007. Application of the GACD required two primary sets of data: survival data and cost data. The survival data included clinical and demographic variables, survival time (i.e. from the date of prostate cancer diagnosis to the date of death) and an indicator for censoring. The cost data included health care utilization costs reimbursed by Medicare for inpatient care, physician/ non-institutional provider care, skilled nursing facility care, outpatient care, home health care, hospice care and durable medical equipment from the date of prostate cancer diagnosis to death or the end of follow-up. All costs were converted to 2009 US dollars (the final year of data collection), using the Consumer Price Index.
On the basis of a review of the literature, including our prior work [6, [8] [9] [10] identifying factors associated with survival and cost accumulation among men diagnosed with prostate cancer, we developed prediction models using prognostic factors and potential cost drivers. The clinical and demographic predictors included the cancer stage, urban residence, age, a proxy indicator for poor performance status and race.
The data required some processing prior to application of the GACD in order to group patients into 'natural' clusters based on a set of variables used to define a patient profile. On the basis of the defined profile characteristics, a 'natural' cluster is defined such that patients within the cluster are more similar to each other than they are to patients outside the cluster [3] . The GACD operated on patient profiles defined using categorical variables of patient characteristics at baseline (see Appendix Table 1 in the Electronic Supplementary Material). For example, assume that a patient profile includes the patient's age at cancer diagnosis, among other variables. Assume further that there are five age categories: 66-69 years, 70-74 years, 75-79 years, 80-84 years and C85 years. We defined the five age categories as shown in Appendix Table 1 and defined additional variables in a similar fashion. A combination was developed by selecting one level from each variable that contributed to defining a patient profile. As illustrated in Appendix Table 2 , if we have five ordered factors-stage, age, race, performance proxy and urban/rural location-the combination '23101' groups patients with an incident diagnosis of stage 2 prostate cancer, diagnosed at an age ranging from 75 to 79 years, of White race, with no pre-diagnosis indication of factors correlated with poor performance status (e.g. hospitalization, skilled nursing facility use, oxygen use) and living in an urban location. These combinations facilitated the data processing in the grouping procedure and provided flexibility in defining factors for use in the grouping exercise.
Analysis: Grouping Patients by Survival Similarity
We first applied the GACD [1] to the formatted data to group patients according to their survival similarity and then generated cost curves for the resulting groups. The algorithm is described in the following steps.
Step 1 We searched for all combinations of different categories for each of the variables used to define patient profiles. The combinations that included \100 individuals were excluded for consistency with underlying statistical assumptions involving the use of the log-rank statistic [3] .
Step 2 The log-rank test was used to initialize the dissimilarity between combinations and then refine it as the learnt dissimilarity by a sequence of non-randomized clustering procedures. The learnt dissimilarity was calculated as follows: suppose there are n combinations {x 1 , x 2 , …, x n } obtained from step 1. The clustering procedures generate n -2 distinct clustering results {C k : k = 2, 3, …, n -1}, where C k is one of the clustering results and k is the number of clusters. A new dissimilarity d k (x i , x j ) between x i and x j is defined as 1 if x i and x j are assigned to the same cluster, and 0 otherwise. However, d k (x i , x j ) should be weighted, since the probability of the two combinations x i , x j falling into different number of clusters may not be equal. That is, a larger k increases the probability that x i , x j will fall into different clusters, so their dissimilarity d k (x i , x j ) should be assigned a smaller weight. The calculation of weight is shown as follows:
The learnt dissimilarity is the average value calculated from n -2 weighted dissimilarities as described above. The following formula shows the calculation of the learnt dissimilarity:
Step 3 An n number of combinations were clustered by application of an agglomerative hierarchical clustering algorithm with the dissimilarity measured from step 2. The hierarchical clustering result is usually represented by a dendrogram [11] . In the GACD, we constructed a dendrogram using the average linkage method [11] . The dendrogram exhibits a similar affinity to the survival curves where the closest survival curves are merged first. Thus, clusters can be obtained through cutting of the dendrogram at a desired level, and each connected component forms a cluster. Figure 1 illustrates the case when there are nine combinations in the survival data. In this case, the dendrogram helped to reduce nine combinations to k(k = 2, 3, …, 6) groups of combinations through cutting of the dendrogram at the appropriate level.
Step 4 We identified groups of patients for plotting cost curves. Use the Kaplan-Meier estimator to plot a survival curve for each of the groups identified in step 3. Figure 2a shows the original survival curves (k = 50) without grouping, based on the prostate cancer data set. Because of the large number of survival curves, the survival curves intertwined and were not well separated. Reducing the survival curves to seven curves (i.e. seven groups, as in Fig. 2b ) reduced but did not eliminate the crossing of curves. Ideally, all survival curves are well separated and will not intertwine. As shown in Fig. 2c , reducing the number of clusters led to survival curves with separation. The maximum number of groups in the non-crossing survival curves was the number of groups we needed for the corresponding cost curves (see Fig. 2d ). The selection process described above illustrates the steps for processing a set of prognostic predictors.
Analysis: Cost Curves and Prediction
The cumulative cost curves were plotted by use of the groups of patients that emerged from step 4 above. For each group of patients, the resulting curves reflect cumulative inverse-probability weighted (IPW) costs for each group [12] . Given the goal of using the curves for prediction, it is important to evaluate the prediction accuracy. We developed two metrics to evaluate the performance of our survival and cost prediction models.
We used 2-fold cross-validation [11] to evaluate the survival model and associated costs. First, we split the survival data into two data sets (D 0 and D 1 ) of equal size.
The data set used to build the algorithm and develop the groups was defined as the 'training data set' (D 0 ). The data set used to apply the resulting groups (i.e., classifier) and then measure the performance of the algorithm was defined as the 'testing data set' (D 1 ). We applied the GACD on D 0 to develop groups of patients that were similar on the basis of the defined characteristics. For the testing part, we dropped all of the combinations from D 1 that did not exist in the groups identified from D 0 . The remaining combinations in D 1 were grouped on the basis of the results from the training data.
We used the grouping algorithm to first create the groups of patients. With those groups, we calculated the predicted costs, as well as the actual cumulative costs, and then calculated the cost difference. The predicted cost is the cumulative cost identified from the training data set (i.e. D 0 ), while the actual cost is the observed cumulative cost identified from the test data set (i.e. D 1 ). The larger the cost difference between the predicted cost and the actual cost, the less accurate the prediction. We investigated the effectiveness of the grouping algorithm for reducing the cost difference by calculating two predicted costs: one generated on the basis of the grouping algorithm and one generated without application of the grouping algorithm. Similarly, we calculated the actual cost with and without the grouping algorithm.
Each patient in the test data set uniquely matches a combination from the training data set. Since each patient record in the test data corresponds to one combination from the training data, each patient record from the test data set can be matched to a group obtained from the training data. The predicted cost for a patient in the test data is equal to the average cumulative cost for the patients in the corresponding group from the training data set. When the predicted cost is generated with the grouping algorithm, the grouping algorithm first generates k groups of patients that correspond to k cumulative cost curves, using the training data set. For a given survival time, k predicted costs are obtained from the k cumulative cost curves. Appendix Fig. 1 in the Electronic Supplementary Material illustrates an example of the distribution of five (k = 5) cost curves derived from the grouped data. Given a survival time of 60 months, we have five different predicted 5-year costs derived from those curves, and these predicted costs will be assigned as the predicted costs for the corresponding patients in the test data. When the predicted cost is generated without using the grouping algorithm, only one cumulative cost curve is plotted. Appendix Fig. 2 illustrates an example of the distribution of one cumulative cost curve plotted using the cost data from all of the patients instead of groups of patients; therefore, all of the patients in the test data share one predicted cost. We calculated the average difference, root mean squared error (RMSE) and mean absolute error (MAE) between the actual cost and predicted cost, including the 95 % confidence interval (CI) of the MAE. A lower value on any of these metrics represents a more accurate prediction.
Results
The study sample included 110,843 men with an incident prostate cancer diagnosis, with a median (mean) followup time of 1430 days (47 months). The majority of the patients were diagnosed with incident stage 2 prostate cancer (55 %). The mean age of the sample was 74 years (standard deviation [SD] 7.3), and 10 % were African American. Approximately 65 % of the patients had a Charlson Comorbidity Index (CCI) score of 0 and 11 % had a CCI score of [2, 1 year prior to prostate cancer diagnosis (i.e. pre-diagnosis CCI score). Ninety percent of the sample resided in an urban location at the time of prostate cancer diagnosis. The training sample included 50,091 patients, and the grouping algorithm identified five groups of patients with similar within-group characteristics. The clinical and demographic characteristics across the resulting five groups are provided in Table 1 . Group 0 included 8897 older Medicare beneficiaries with incident prostate cancer. The majority (75 %) of the men in group 0 were aged C75 years, 8 % were African American and approximately 61 % had a pre-diagnosis CCI score of 0. Group 1 included 7572 beneficiaries with incident prostate cancer. The majority (80 %) of the men in group 1 were aged C75 years, 15 % were African American and approximately 55 % had a pre-diagnosis CCI score of 0. Group 2 included 29,006 beneficiaries with incident prostate cancer. A smaller proportion of men in group 2 were aged C75 years (19 %), 6 % were African American and approximately 71 % had a CCI score of 0. Group 3 included 2727 beneficiaries with Table 1 . There was variation across the groups in terms of clinical and demographic measures. Group 4 had the highest proportion of men (77 %) with stage 4 prostate cancer at diagnosis, the highest proportion of older men (92 % diagnosed at an age of C80 years), the highest proportion (25 %) with a CCI score of C2 and the highest proportion (52 %) with pre-diagnosis indicators of proxies for poor performance status. All individuals in group 4 were White men living in urban settings. This group also reported the shortest time to death (601 days), the shortest follow-up time (742 days) and the largest mortality proportion (86 % for all-cause death and 57 % for prostate cancer-related death). In contrast, group 2 had the highest proportion of men (67 %) diagnosed with stage 2 prostate cancer, the lowest proportion of older men (0.5 % diagnosed at an age of C80 years), the lowest proportion (6 %) with a missing CCI score and the lowest proportion (2 %) with pre-period indicators of proxies for poor performance status. Approximately 90 % of the men in group 2 were White, while 6 % were African American and 4 % belonged to the 'other' race group. The majority of the men in group 2 lived in urban settings (92 %). This group also reported the second-longest average time to death (1263 days), the second-longest average follow-up time (1618 days) and the lowest mortality proportion (17 % for all-cause death and 11 % for prostate cancer-related death).
The differences in predictions with and without grouping are presented in Table 2 . The MAE (95 % CI) values were US$41,790 (US$41,421-42,158) with grouping and US$43,639 (US$43,062-44,217) without grouping. Whether based on the average difference, RMSE or MAE, the grouping algorithm (utilizing group-specific average costs) resulted in an improved prediction of average total costs at 5 years in comparison with a method based on the average cost for the full sample. The 5-year cost prediction without grouping summed to a sample overestimate of US$79,544,508.
Discussion
Decision makers, including insurance companies and providers, are interested in identifying factors that predict cost accumulation. Cost analyses that are purely hypothesis driven may result in missed opportunities to enrich our understanding of the important predictive factors for cost accumulation. At the same time, analyses that are purely data driven may be inefficient in that they do not incorporate available evidence regarding cost predictors. A hybrid approach that combines data-driven investigations with available evidence can yield unique insights and identify important factors contributing to increasing cancer care costs in the USA. Using a published grouping algorithm [1] , we investigated the usefulness of grouping algorithms for cost prediction. A secondary goal was to illustrate the utility of data-driven approaches for generating insights regarding important demographic and clinical predictors of costs.
Grouping algorithms for analysing patient groups have been applied to studying survival among cancer patients [3] . These grouping algorithms identified similar patients The column percentage is calculated as the ratio of the frequency count for a single cell to the total frequency count for the column that contains the cell. The ratio is represented as a percentage, e.g. the column percentage for Whites in group 1 = (867/5420) 9 100 = 16.0 % e P values were calculated using Chi squared tests on the basis of their entire survival experience. Examination of the resulting groups yielded insight into combinations of levels of factors associated with poorer survival, not all of which were identified by hypothesis-driven analysis. Each group resulting from the application of the grouping algorithm is composed of different combinations (see Appendix Table 2 in the Electronic Supplementary Material for an illustration). These combinations facilitate the data processing in the grouping procedure, provide flexibility in defining factors for use in the grouping exercise and facilitate the interpretation of results from the grouping exercise. Combinations grow exponentially as the number of factors and the number of levels per factor increase. Thus, the method is particularly suited to large data sets, permitting large cell sizes within each categorization of factors used in the grouping algorithm. On its own, the cost pattern over time can provide information regarding the underlying clinical health status, e.g. increasing costs associated with hospitalizations signal a decline in health status. When combined with a prognostic tool that describes cost accumulation over time, individuals who are more likely to experience future declines in health status can be identified earlier, providing care providers with time to identify the clinical and care resources that are appropriate for the patient. Lastly, basing the prognostic tool on an approach that incorporates multiple characteristics (not all of which would be patient-level characteristics) opens up possibilities for investigating survival and cost accumulation in a diverse, 'real-world' patient population. The resulting cost accumulation predictions, as well as the associated care, can then be better tailored to the patients.
The application of the grouping algorithm is an 'informed data-driven' approach. While the results (i.e. groupings) are purely data driven, the choice of the initial candidate set of measures could be based on prior information regarding cost drivers. The results imply that we may need larger samples and more predictors to separate the cost curves. The results also show the variation in the relative order of cost predictions during the follow-up period. For example, group 4 remains the costly group until 96 months of follow-up, later to be overtaken by groups 1 and 3. This informed data-driven analysis can yield unique insights. For example, group 4 had the highest mortality rate. Group 4 also had the highest proportion of individuals with a CCI score of C2 during the pre-period, the highest proportion of individuals with at least one performance status proxy indicator in the year prior to prostate cancer diagnosis and the highest proportion of individuals with no health service use in the period prior to diagnosis. Prior research has noted that individuals with health service use in the period prior to diagnosis are more likely to follow up with their urologist post-diagnosis [13] , thus it would be interesting to understand patterns of urologist follow-up among group 4 patients. Groups 1 and 3 are interesting to consider from a cost standpoint, given the escalating costs over time. Both groups reported the highest proportion of individuals with a CCI score of C2 during the post-period across all groups, which indicates that there is an association between multiple comorbidity and future costs. Group 1 is interesting to note because it has the highest proportion of African Americans (15 %) among all groups, while group 3 is interesting to note because it has the largest number of individuals with an 'unknown' cancer stage across all groups (58 %). If there is an interest in further investigating cost drivers on the basis of the care setting, the curves in Fig. 2d can be produced separately for inpatient costs.
Prior studies on the costs of prostate cancer [6] have mostly focused on providing the cost of illness, with a few papers also providing cost projections [14, 15] . Outside the prostate cancer setting, there has been some attention paid to data-driven methods for predicting future costs and/or identifying important predictors [16] [17] [18] . The predictions can be useful to inform patient decision making [19] , perform risk adjustment [20] or provide cost information for an insurer or large employer [18] . Only a few studies have investigated the accuracy of the annual cost predictions, and even fewer have investigated the accuracy of cost predictions beyond 12 months. Fishman et al. [20] compared the accuracy of several risk adjustment tools, including a pharmacy-based risk adjustment tool, the CI confidence interval, MAE mean absolute error, RMSE root mean squared error a Cost difference between predicted cost derived from similar groups of patients created by the grouping algorithm in the training data set and actual cumulative cost obtained from patients in the test data set. The larger the cost difference between the predicted cost and the actual cost, the less accurate the prediction Ambulatory Clinical Groups (ACG) tool and the Hierarchical Coexisting Conditions (HCC) tool. They found the HCC tool to be the most accurate at predicting future health care costs and noted that the advantage of the HCC was diminished (even disappearing) for certain population subgroups.
Our analysis provides a systematic, reproducible approach to grouping patients on the basis of survival and, notably, prior to considering costs. Grouping patients prior to cost estimation improves the accuracy of the prediction by utilizing the average costs from a similar group of patients rather than the average costs in the full sample of patients. This tailoring of the cost prediction is intuitive, patient centred and well suited to real-world applications. Alternatively, the grouped cost curves could be used prospectively to identify patient profiles that are likely to cost more at specific time points. For example, an insurer may be interested in either characterizing high-cost patients at 12 months following enrolment or predicting what a new enrolee with a specific profile (e.g. an 85-year-old Hispanic man who has pre-existing diabetes, is diagnosed with stage 4 prostate cancer and resides in a rural town) will cost in 12 months. In the former case, the decision maker examines the highest grouped cost curve at the 12-month mark, while in the latter case, the decision maker reads off the grouped cost curve to which the patient belongs to identify the cost at the 12-month mark.
As with any study using claims data, there are a few limitations to note. The study utilized the linked Medicare claims data for the prostate cancer cases identified in SEER. The results may not be generalizable to younger men diagnosed with prostate cancer, who may present with a different clinical profile, resulting in different groupings and cost predictions. While the grouping algorithm improved upon the cost prediction compared with the prediction based on sample averages, the absolute difference in 5-year costs exceeded US$40,000. The incorporation of factors such as smoking status, performance status and body mass index may improve the 5-year cost prediction and reduce the absolute difference between predicted and actual costs. Utilizing the grouping algorithm procedure with linked claims and electronic medical records would provide a richer set of clinical measures, which, when combined with the cost data from the claims, would greatly enrich our understanding of the important clinical and demographic factors that impact costs and predict costs over time. This study does not identify a definitive set of predictors for entering into the grouping algorithm. Rather, it illustrates how use of the grouping algorithm can improve cost prediction and identify cost drivers on the basis of a candidate set of predictors. While the methods would remain broadly applicable, the findings of this study are generalizable only to the older Medicare population in the USA. The study findings may not be generalizable to older men enrolled in health maintenance organizations and Medicare Advantage plans, or men residing outside the USA.
Conclusion
The grouping algorithm can be used by public health decision makers to understand patients who are likely to cost more in the future, it can be used by insurers/payers to identify high-cost patients who may be suited to coordinated care (e.g. patients with high comorbidity) and it can be used by patients to understand the future costs associated with various health conditions and behavioural factors (e.g. the contribution of smoking to future health care costs). The approach is an 'informed data-driven' approach in that the data-driven search for similar patient groups builds on an informed set of predictors. A purely data-driven approach can be used with even larger data sets, in which the algorithm identifies the important factors. Future research using this method should utilize even larger data sets for cost prediction to gain the full benefit of this approach.
interpretation of the analysis; and drafted and revised the manuscript with input from all co-authors. Ran Qi contributed to the study design, conduct of the analysis and interpretation of the analysis; and drafted the manuscript with input from all co-authors. Jinani Jayasekera contributed to the data analysis; and reviewed and commented on/ edited all drafts of the manuscript. Shujia Zhou contributed to the study design and interpretation of the analysis; and reviewed and commented on/edited all drafts of the manuscript. Eberechukwu Onukwugha acts as the guarantor for the overall content.
